Qube Research & Technologies (QRT)
OCUL icon

Qube Research & Technologies (QRT)’s Ocular Therapeutix OCUL Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.5M Sell
531,816
-237,958
-31% -$2.27M 0.01% 1718
2025
Q4 		$9.35M Buy
769,774
+738,922
+2,395% +$8.98M 0.01% 1385
2025
Q3 		$361K Buy
+30,852
New +$369K ﹤0.01% 2801
2022
Q1 		– Sell
-78,242
Closed -$545K – 2839
2021
Q4 		$545K Buy
78,242
+46,617
+147% +$362K ﹤0.01% 1523
2021
Q3 		$316K Sell
31,625
-65,346
-67% -$734K ﹤0.01% 1466
2021
Q2 		$1.38M Buy
96,971
+76,202
+367% +$1.16M 0.02% 823
2021
Q1 		$341K Buy
+20,769
New +$400K 0.01% 1392
2020
Q3 		– Sell
-44,349
Closed -$369K – 1988
2020
Q2 		$369K Buy
+44,349
New +$294K 0.01% 1227

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return